Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007409 | 0.82 | AKR1C3 (0.51) | LTA4HCYP2D6CYP2C19TSHRALDH1A1 | |
| SCHEMBL447088 | 0.79 | LTA4H (0.72) | SLC18A3SIGMAR1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL13660519 | 0.76 | SLC18A3 (0.57) | SLC18A3SIGMAR1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL1587410 | 0.75 | AKR1C3 (0.54) | SLC18A3AGTR2 | |
| SCHEMBL27894548 | 0.73 | CYP2D6 (0.65) | SLC18A3CYP2D6CYP2C19SMN1; SMN2AGTR2 | |
| SCHEMBL5009505 | 0.71 | ALDH1A1 (0.48) | LTA4HSMN1; SMN2ALDH1A1AGTR2 | |
| SCHEMBL444560 | 0.70 | AKR1C3 (0.56) | SLC18A3SIGMAR1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL5004640 | 0.70 | ALDH1A1 (0.50) | SLC18A3LTA4HTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL6373468 | 0.70 | CYP2D6 (0.59) | SLC18A3CYP2D6CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL6627476 | 0.69 | HRH3 (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | SLC18A3 3846/4885SIGMAR1 190/4885LTA4H 2266/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | SLC18A3 3846/4885SIGMAR1 190/4885LTA4H 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.